Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.
复制标题
DOI：
10.1097/pas.0000000000000208
复制
发表时间：
2014-06
期刊：
影响因子：
--
通讯作者：
Rubin MA
中科院分区：
文献类型：
--
作者：
Epstein JI;Amin MB;Beltran H;Lotan TL;Mosquera JM;Reuter VE;Robinson BD;Troncoso P;Rubin MA
2013年7月31日，前列腺癌基金会组建了前列腺癌神经内分泌分化的分子生物学和病理分类工作委员会。该委员会由具有该领域专业知识的泌尿生殖肿瘤学家、泌尿科医生、泌尿外科病理学家、基础科学家和转化研究人员组成。结论是，会议记录应以两份手稿进行报道，以吸引不同的目标受众，一份重点关注外科病理学，另一份审查该疾病的分子方面。现代雄激素剥夺疗法治疗的前列腺癌以及原发性病变的新临床和分子数据强调需要完善诊断术语以涵盖神经内分泌分化的全谱。预计与改进的诊断术语相关的具体标准将导致临床相关的病理诊断，这将刺激进一步的临床和分子研究以及适当的靶向治疗的识别。
On July 31, 2013, the Prostate Cancer Foundation assembled a working committee on the molecular biology and pathologic classification of neuroendocrine differentiation in prostate cancer. The committee consisted of genitourinary oncologists, urologists, urological surgical pathologists, basic scientists, and translational researchers, with expertise in this field. It was concluded that the proceedings of the meeting should be reported in 2 manuscripts appealing to different target audiences, one to focus on surgical pathology and the other to review the molecular aspects of this disease. New clinical and molecular data emerging from prostate cancers treated by contemporary androgen deprivation therapies, as well as primary lesions, have highlighted the need for refinement of diagnostic terminology to encompass the full spectrum of neuroendocrine differentiation. It is envisioned that specific criteria associated with the refined diagnostic terminology will lead to clinically relevant pathologic diagnoses that will stimulate further clinical and molecular investigation and identification of appropriate targeted therapies.